Heimdall Insights

Global Ultomiris Drug Market

Sizing, Segmentation, & Growth Forecast (2025-2030)

Last updated: August 2026

Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.

Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).

1. Summary

The Global Ultomiris Drug Market was valued at $5.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 26.5% CAGR, to an estimated market size of $16.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The Global Ultomiris Drug Market encompasses the commercialization and therapeutic application of ravulizumab, a long-acting humanized monoclonal antibody and C5 complement inhibitor. It is primarily indicated for the treatment of rare, life-threatening complement-mediated disorders including Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder (NMOSD).

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Ultomiris Drug Market in the period 2025-30:

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:

Geographies

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Segments

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Generalized Myasthenia Gravis (gMG)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)